A phase i study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumors

Andrea Wang-Gillam; William P. Tew; Mac E L Rothenberg; Jakob Dupont; Wendy Cooper; Lars Sternas; Giliane Buzenet; Jeffrey A. Sosman; David R. Spriggs; Albert Craig Lockhart

doi:10.1007/s10637-011-9753-y

A phase i study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumors

Andrea Wang-Gillam, William P. Tew, Mac E L Rothenberg, Jakob Dupont, Wendy Cooper, Lars Sternas, Giliane Buzenet, Jeffrey A. Sosman, David R. Spriggs, Albert Craig Lockhart^*

^*Corresponding author for this work

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

Summary: Targeting angiogenesis is a valid anti-cancer strategy. Aflibercept is designed to sequester circulating vascular endothelial growth factor (VEGF) by preventing VEGF from binding to its receptors. This phase I study was to evaluate a new formulation of subcutaneously administered aflibercept in patients with advanced solid tumors. Here we report our experience with the toxicity, pharmacokinetic profile and efficacy of the new 100 mg/mL subcutaneous (SC) formulation of aflibercept administered at a dose of at 4 mg/kg every 2 weeks.

Original language	English (US)
Pages (from-to)	1958-1961
Number of pages	4
Journal	Investigational New Drugs
Volume	30
Issue number	5
DOIs	https://doi.org/10.1007/s10637-011-9753-y
State	Published - Oct 2012

Keywords

Aflibercept
Angiogenesis inhibitor
Phase I study
Subcutaneously administration

ASJC Scopus subject areas

Oncology
Pharmacology
Pharmacology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s10637-011-9753-y

Cite this

Wang-Gillam, A., Tew, W. P., Rothenberg, M. E. L., Dupont, J., Cooper, W., Sternas, L., Buzenet, G., Sosman, J. A., Spriggs, D. R., & Lockhart, A. C. (2012). A phase i study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumors. Investigational New Drugs, 30(5), 1958-1961. https://doi.org/10.1007/s10637-011-9753-y

@article{93f23dc7c5ea4953b86889be04402ff6,

title = "A phase i study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumors",

abstract = "Summary: Targeting angiogenesis is a valid anti-cancer strategy. Aflibercept is designed to sequester circulating vascular endothelial growth factor (VEGF) by preventing VEGF from binding to its receptors. This phase I study was to evaluate a new formulation of subcutaneously administered aflibercept in patients with advanced solid tumors. Here we report our experience with the toxicity, pharmacokinetic profile and efficacy of the new 100 mg/mL subcutaneous (SC) formulation of aflibercept administered at a dose of at 4 mg/kg every 2 weeks.",

keywords = "Aflibercept, Angiogenesis inhibitor, Phase I study, Subcutaneously administration",

author = "Andrea Wang-Gillam and Tew, {William P.} and Rothenberg, {Mac E L} and Jakob Dupont and Wendy Cooper and Lars Sternas and Giliane Buzenet and Sosman, {Jeffrey A.} and Spriggs, {David R.} and Lockhart, {Albert Craig}",

year = "2012",

month = oct,

doi = "10.1007/s10637-011-9753-y",

language = "English (US)",

volume = "30",

pages = "1958--1961",

journal = "Investigational New Drugs",

issn = "0167-6997",

publisher = "Kluwer Academic Publishers",

number = "5",

}

TY - JOUR

T1 - A phase i study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumors

AU - Wang-Gillam, Andrea

AU - Tew, William P.

AU - Rothenberg, Mac E L

AU - Dupont, Jakob

AU - Cooper, Wendy

AU - Sternas, Lars

AU - Buzenet, Giliane

AU - Sosman, Jeffrey A.

AU - Spriggs, David R.

AU - Lockhart, Albert Craig

PY - 2012/10

Y1 - 2012/10

N2 - Summary: Targeting angiogenesis is a valid anti-cancer strategy. Aflibercept is designed to sequester circulating vascular endothelial growth factor (VEGF) by preventing VEGF from binding to its receptors. This phase I study was to evaluate a new formulation of subcutaneously administered aflibercept in patients with advanced solid tumors. Here we report our experience with the toxicity, pharmacokinetic profile and efficacy of the new 100 mg/mL subcutaneous (SC) formulation of aflibercept administered at a dose of at 4 mg/kg every 2 weeks.

AB - Summary: Targeting angiogenesis is a valid anti-cancer strategy. Aflibercept is designed to sequester circulating vascular endothelial growth factor (VEGF) by preventing VEGF from binding to its receptors. This phase I study was to evaluate a new formulation of subcutaneously administered aflibercept in patients with advanced solid tumors. Here we report our experience with the toxicity, pharmacokinetic profile and efficacy of the new 100 mg/mL subcutaneous (SC) formulation of aflibercept administered at a dose of at 4 mg/kg every 2 weeks.

KW - Aflibercept

KW - Angiogenesis inhibitor

KW - Phase I study

KW - Subcutaneously administration

UR - http://www.scopus.com/inward/record.url?scp=84867847536&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867847536&partnerID=8YFLogxK

U2 - 10.1007/s10637-011-9753-y

DO - 10.1007/s10637-011-9753-y

M3 - Article

C2 - 22002018

AN - SCOPUS:84867847536

SN - 0167-6997

VL - 30

SP - 1958

EP - 1961

JO - Investigational New Drugs

JF - Investigational New Drugs

IS - 5

ER -

A phase i study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumors

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this